Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AbbVie Inc.ABBV · Entity 2800 | SVP, CSO, GLOBAL RESEARCH | February 28, 2024 | March 01, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AbbVie Inc.
Report date February 28, 2024 · Filed March 01, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 107,267 |
Reported balance
After 2024-02-28 transaction · row 1
1 source rowRow 1 · 2024-02-28 · Tax withholding · Disposed 20,634 · Balance 107,267 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2024 Filed Mar 1, 2024 22:50 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 20,634 | $178.99 | $3,693,279.66 |
DisclosureSEC source: 0001415889-24-006158 · form4-03012024_050307.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,267 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 18,912 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004418 · form4-02202024_050219.xml · derivative · entry 5 Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,912 Underlying: Common Stock · 18,912 shares Expires 2034-02-14 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,304 on February 15, 2025, 6,304 on February 15, 2026, and 6,304 on February 15, 2027. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,348 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004418 · form4-02202024_050219.xml · nonDerivative · entry 4 Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,901 F4 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004418 · form4-02202024_050219.xml · nonDerivative · entry 3 Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 122,553 F3 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 7,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004418 · form4-02202024_050219.xml · nonDerivative · entry 2 Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,203 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on invested capital measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:15 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 28,322 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004418 · form4-02202024_050219.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, CSO, GLOBAL RESEARCH 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,651 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2024. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:35 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 27,922 | $154.28 | $4,307,806.16 |
DisclosureSEC source: 0001415889-23-003844 · form4-03022023_040301.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,329 Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 20,256 | $0.00 Strike: $149.62 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · derivative · entry 5 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,256 Underlying: Common Stock · 20,256 shares Expires 2033-02-15 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 6,752 on February 16, 2024, 6,752 on February 16, 2025, and 6,752 on February 16, 2026. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 5,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · nonDerivative · entry 4 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,251 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 7,552 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · nonDerivative · entry 3 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,901 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 9,481 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · nonDerivative · entry 2 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,349 F2 · shares: Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 23:07 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 40,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002940 · form4-02212023_110258.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D AND CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,868 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2023. Read SEC document |
| February 25, 2022 Filed Mar 1, 2022 23:09 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 13,408 | $149.54 | $2,005,032.32 |
DisclosureSEC source: 0001179110-22-001835 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,228 Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (Right to Buy) · Derivative | 25,394 | $0.00 Strike: $144.54 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · derivative · entry 5 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,394 Underlying: Common Stock · 25,394 shares Expires 2032-02-16 F5 · security: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 8,465 on February 17, 2023, 8,465 on February 17, 2024, and 8,465 on February 17, 2025. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · nonDerivative · entry 4 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,636 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 18, 2021. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 9,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · nonDerivative · entry 3 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,027 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · nonDerivative · entry 2 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,544 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 17, 2022 Filed Feb 22, 2022 22:33 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 11,642 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001509 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,014 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2022. Read SEC document |
| February 28, 2021 Filed Mar 3, 2021 01:29 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 7,740 | $107.74 | $833,907.60 |
DisclosureSEC source: 0001179110-21-002599 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,372 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption(right to buy) · Derivative | 37,267 | $0.00 Strike: $105.92 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · derivative · entry 5 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,267 Underlying: Common stock · 37,267 shares Expires 2031-02-17 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,423 on February 18, 2022 12,422 on February 18, 2023, and 12,422 on February 18, 2024. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 9,483 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · nonDerivative · entry 4 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,112 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 20, 2020. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · nonDerivative · entry 3 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,629 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · nonDerivative · entry 2 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,099 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 23:17 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 4,216 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-002045 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,859 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2021. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:54 UTC | AbbVie Inc. ABBV · Entity 2800 | Tax withholdingCommon Stock, $0.01 par value | 5,477 | $85.42 | $467,845.34 |
DisclosureSEC source: 0001179110-20-002856 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,643 Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:02 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantOption (right to buy) · Derivative | 62,193 | $0.00 Strike: $93.50 | $0.00 |
DisclosureSEC source: 0001179110-20-002134 · edgar.xml · derivative · entry 5 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,193 Underlying: Common Stock · 62,193 shares Expires 2030-02-19 F5 · security: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,731 on February 20, 2021, 20,731 on February 20, 2022, and 20,731 on February 20, 2023. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:02 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002134 · edgar.xml · nonDerivative · entry 4 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,120 F4 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 21, 2019. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:02 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 1,239 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002134 · edgar.xml · nonDerivative · entry 3 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,588 F3 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 15, 2018. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:02 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 2,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002134 · edgar.xml · nonDerivative · entry 2 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,349 F2 · shares: Represents shares of AbbVie common stock issued under a performance vesting restricted stock unit award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 23:02 UTC | AbbVie Inc. ABBV · Entity 2800 | GrantCommon Stock, $0.01 par value | 6,321 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002134 · edgar.xml · nonDerivative · entry 1 Hudson Thomas J · CIK 0001781947 · SVP, R&D and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,069 F1 · shares: Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 16, 2017. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.